サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1720754

慢性炎症性脱髄性多発神経炎（CIDP）の世界市場レポート 2025年

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.28円
慢性炎症性脱髄性多発神経炎（CIDP）の世界市場レポート 2025年
出版日: 2025年05月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

慢性炎症性脱髄性多発神経炎（CIDP）市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は8.1％で、31億1,000万米ドルに成長します。予測期間中の成長は、世界人口の高齢化、希少疾患と自己免疫疾患への注目の高まり、ヘルスケアへのアクセスの改善、患者擁護と意識向上キャンペーンの増加、ヘルスケアインフラの進歩によるものと考えられます。主な動向としては、慢性炎症性脱髄性多発神経炎の有病率の上昇、治療選択肢の進展、研究開発活動の拡大、バイオシミラー治療の出現、個別化医療アプローチの開発などが挙げられます。

ヘルスケア支出の増加は、慢性炎症性脱髄性多発神経炎（CIDP）市場の成長を促進すると予想されます。医療支出の増加は、医療インフラへの投資、先進治療への需要の増加、保険適用範囲の拡大、医療アクセスを改善するための政府の取り組みによって促進されています。ヘルスケア支出が増加するにつれて、CIDPの最先端治療、早期診断、より良い管理へのアクセスが強化され、これらすべてが患者の転帰とQOLの向上に寄与します。例えば、英国の政府機関である国家統計局は2024年5月、2022年から2023年にかけての総ヘルスケア支出が5.6%増加すると報告しています。このようなヘルスケア支出の増加が、CIDP市場を後押ししています。

CIDP市場の主要企業は、治療効果を改善し、患者の転帰を改善し、CIDPの管理により的を絞った免疫調節を提供するために、免疫グロブリン静注療法（IVIG）などの進歩に注目しています。IVIG療法では、健康なドナーから濃縮した抗体を注入することで、免疫系を調節し、自己免疫疾患における炎症を抑えます。例えば、2024年1月、日本のバイオ医薬品会社である武田薬品工業株式会社は、成人のCIDP患者に対するIVIG療法としてガンマガード液剤のFDA承認を取得しました。この承認により、長期的な疾患管理と神経筋機能の改善を目的とした、初回投与後の維持投与による導入療法としての使用が可能となりました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界慢性炎症性脱髄性多発神経炎（CIDP） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場：成長率分析
  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場の実績：規模と成長, 2019-2024
  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場の予測：規模と成長, 2024-2029, 2034F
  • 世界慢性炎症性脱髄性多発神経炎（CIDP）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 静脈内免疫グロブリン
  • コルチコステロイド
  • 血漿交換
  • 理学療法
  • その他の治療法
  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 静脈内
  • オーラル
  • その他の投与経路
  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 電気診断検査
  • 神経伝導
  • 筋電図検査（EMG）
  • 脊髄液分析
  • その他の診断
  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • 薬局
  • オンライン薬局
  • 専門クリニック
  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • 調査機関
  • 在宅ケア設定
  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 経口コルチコステロイド
  • 静脈内コルチコステロイド
  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場、血漿交換療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 単回交換血漿交換療法
  • 多回交換血漿交換療法
  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場理学療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 筋力強化エクササイズ
  • バランスと協調療法
  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 免疫抑制剤
  • モノクローナル抗体

第7章 地域別・国別分析

  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の慢性炎症性脱髄性多発神経炎（CIDP）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 慢性炎症性脱髄性多発神経炎（CIDP）市場：競合情勢
  • 慢性炎症性脱髄性多発神経炎（CIDP）市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Baxter International Inc.
  • CSL Behring（CSL Limited）
  • Grifols S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Octapharma AG
  • Cipla Inc.
  • Hikma Pharmaceuticals plc
  • Halozyme Therapeutics
  • Hualan Biological Engineering Inc
  • argenx SE
  • Hovione
  • Nihon Pharmaceutical Co. Ltd.
  • Bio Products Laboratory Ltd.
  • AdvaCare Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 慢性炎症性脱髄性多発神経炎（CIDP）市場2029：新たな機会を提供する国
  • 慢性炎症性脱髄性多発神経炎（CIDP）市場2029：新たな機会を提供するセグメント
  • 慢性炎症性脱髄性多発神経炎（CIDP）市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34010

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder characterized by progressive weakness and impaired sensory function due to nerve inflammation and demyelination. It occurs when the immune system attacks the myelin sheath of peripheral nerves, leading to muscle weakness, numbness, and coordination difficulties.

The primary treatment options for CIDP include intravenous immunoglobulin (IVIg), corticosteroids, plasmapheresis, physiotherapy, and other supportive therapies. IVIg is a blood-derived product containing antibodies that help regulate the immune system and treat autoimmune, immune deficiency, and inflammatory conditions. These treatments are administered through various routes, including intravenous, oral, and others. Diagnosis typically involves electrodiagnostic testing, nerve conduction studies, electromyography (EMG), spinal fluid analysis, and other diagnostic procedures. Treatments are distributed through hospitals, pharmacies, online pharmacies, and specialty clinics, with key end users including hospitals, research institutions, and homecare settings.

The chronic inflammatory demyelinating polyneuropathy (CIDP) market research report is one of a series of new reports from The Business Research Company that provides chronic inflammatory demyelinating polyneuropathy (CIDP) market statistics, including the chronic inflammatory demyelinating polyneuropathy (CIDP) industry global market size, regional shares, competitors with the chronic inflammatory demyelinating polyneuropathy (CIDP) market share, detailed chronic inflammatory demyelinating polyneuropathy (CIDP) market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic inflammatory demyelinating polyneuropathy (CIDP) industry. This chronic inflammatory demyelinating polyneuropathy (CIDP) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic inflammatory demyelinating polyneuropathy (CIDP) market size has grown strongly in recent years. It will grow from $2.10 billion in 2024 to $2.38 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be credited to the increasing geriatric population, advancements in treatment options, greater awareness and early diagnosis, progress in immunology and autoimmune research, and the rising prevalence of autoimmune diseases.

The chronic inflammatory demyelinating polyneuropathy (CIDP) market size is expected to see strong growth in the next few years. It will grow to $3.11 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth during the forecast period can be credited to an aging global population, a growing focus on rare diseases and autoimmune disorders, improved access to healthcare, increased patient advocacy and awareness campaigns, and advancements in healthcare infrastructure. Key trends include the rising prevalence of chronic inflammatory demyelinating polyneuropathy, advancements in treatment options, expanding research and development activities, the emergence of biosimilar therapies, and the development of personalized medicine approaches.

The increasing healthcare expenditure is expected to drive the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market. The rise in healthcare spending is fueled by investments in medical infrastructure, increased demand for advanced treatments, expanded insurance coverage, and government efforts to improve healthcare access. As healthcare expenditure grows, it enhances access to cutting-edge treatments, early diagnosis, and better management of CIDP, all of which contribute to improved patient outcomes and quality of life. For instance, in May 2024, the Office for National Statistics, a UK-based government agency, reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, a notable acceleration compared to the 0.9% growth seen in 2022. This growing healthcare expenditure is thus propelling the CIDP market.

Leading companies in the CIDP market are focusing on advancements such as intravenous immunoglobulin (IVIG) therapy to improve treatment effectiveness, enhance patient outcomes, and offer more targeted immune modulation for managing CIDP. IVIG therapy involves infusing concentrated antibodies from healthy donors to help modulate the immune system and reduce inflammation in autoimmune conditions. For example, in January 2024, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, received FDA approval for GAMMAGARD LIQUID as an IVIG therapy for adults with CIDP. This approval allows its use as an induction therapy, with an initial dose followed by maintenance doses to manage long-term disease and improve neuromuscular function.

In November 2024, Zai Lab Limited, a China-based biopharma company, partnered with argenx SE to introduce VYVGART Hytrulo as the first approved subcutaneous injection for CIDP in China. This partnership aims to provide a convenient, effective, and well-tolerated treatment, addressing unmet medical needs and improving patient outcomes. Argenx SE, a Netherlands-based biotechnology company, focuses on advancing therapies for severe autoimmune diseases, including CIDP.

Major players in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., and AdvaCare Pharma.

North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic inflammatory demyelinating polyneuropathy (CIDP) market consists of revenues earned by entities by providing services such as diagnostic testing, patient management, and therapeutic treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic inflammatory demyelinating polyneuropathy (CIDP) market also includes sales of plasma exchange devices, monoclonal antibodies, nerve conduction study equipment, and physical therapy aids. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic inflammatory demyelinating polyneuropathy (cidp) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic inflammatory demyelinating polyneuropathy (cidp) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic inflammatory demyelinating polyneuropathy (cidp) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment: Intravenous Immunoglobulin; Corticosteroids; Plasmapheresis; Physiotherapy; Other Treatments
  • 2) By Route Of Administration: Intravenous; Oral; Other Routes Of Administration
  • 3) By Diagnosis: Electrodiagnostic Testing; Nerve Conduction; Electromyography (EMG); Spinal Fluid Analysis; Other Diagnosis
  • 4) By Distribution Channel: Hospitals; Pharmacies; Online Pharmacies; Specialty Clinics
  • 5) By End User: Hospitals; Research Institutions; Homecare Settings
  • Subsegments:
  • 1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy; High-Dose IVIG Therapy
  • 2) By Corticosteroids: Oral Corticosteroids; Intravenous Corticosteroids
  • 3) By Plasmapheresis: Single-Exchange Plasmapheresis; Multiple-Exchange Plasmapheresis
  • 4) By Physiotherapy: Muscle Strengthening Exercises; Balance And Coordination Therapy
  • 5) By Other Treatments: Immunosuppressive Agents; Monoclonal Antibodies
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Sanofi SA; Novartis AG; Takeda Pharmaceutical Company Limited
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Characteristics

3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends And Strategies

4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate Analysis
  • 5.4. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Addressable Market (TAM)

6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segmentation

  • 6.1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Intravenous Immunoglobulin
  • Corticosteroids
  • Plasmapheresis
  • Physiotherapy
  • Other Treatments
  • 6.2. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Intravenous
  • Oral
  • Other Route of Administration
  • 6.3. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Electrodiagnostic Testing
  • Nerve Conduction
  • Electromyography (EMG)
  • Spinal Fluid Analysis
  • Other Diagnosis
  • 6.4. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Pharmacies
  • Online Pharmacies
  • Specialty Clinics
  • 6.5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Research Institutions
  • Homecare Settings
  • 6.6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral Corticosteroids
  • Intravenous Corticosteroids
  • 6.7. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Plasmapheresis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Single-Exchange Plasmapheresis
  • Multiple-Exchange Plasmapheresis
  • 6.8. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Physiotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Muscle Strengthening Exercises
  • Balance And Coordination Therapy
  • 6.9. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immunosuppressive Agents
  • Monoclonal Antibodies

7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Regional And Country Analysis

  • 7.1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 8.1. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 9.1. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
  • 9.2. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 10.1. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 11.1. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
  • 11.2. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 12.1. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 13.1. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 14.1. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
  • 14.2. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 15.1. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
  • 15.2. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 16.1. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 17.1. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 18.1. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 19.1. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 20.1. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 21.1. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
  • 21.2. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 22.1. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 23.1. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
  • 23.2. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 24.1. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
  • 24.2. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 25.1. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
  • 25.2. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 26.1. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
  • 26.2. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 27.1. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 28.1. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
  • 28.2. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

  • 29.1. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
  • 29.2. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Landscape And Company Profiles

  • 30.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Landscape
  • 30.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Other Major And Innovative Companies

  • 31.1. Baxter International Inc.
  • 31.2. CSL Behring (CSL Limited)
  • 31.3. Grifols S.A.
  • 31.4. Sun Pharmaceutical Industries Ltd.
  • 31.5. Mitsubishi Tanabe Pharma Corporation
  • 31.6. Octapharma AG
  • 31.7. Cipla Inc.
  • 31.8. Hikma Pharmaceuticals plc
  • 31.9. Halozyme Therapeutics
  • 31.10. Hualan Biological Engineering Inc
  • 31.11. argenx SE
  • 31.12. Hovione
  • 31.13. Nihon Pharmaceutical Co. Ltd.
  • 31.14. Bio Products Laboratory Ltd.
  • 31.15. AdvaCare Pharma

32. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

34. Recent Developments In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

35. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market High Potential Countries, Segments and Strategies

  • 35.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer